Generated by AI
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on developing and commercializing therapies for immune-mediated skin diseases. The company’s portfolio centers on ZORYVE, a branded treatment platform that includes topical formulations used in conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and psoriasis in sensitive areas. Arcutis also advances a pipeline of dermatology candidates, including additional topical and systemic programs designed to address inflammatory skin disorders with high unmet medical need. Its research and development approach combines dermatology expertise with targeted drug development against biologically validated pathways, positioning the company as a specialist player in the medical dermatology market. Based in Westlake Village, California, Arcutis Biotherapeutics serves patients, dermatology clinicians, and healthcare providers through prescription therapies aimed at chronic skin conditions.
Website3027 Townsgate Road
Westlake Village, CA, 91361
United States
The latest articles about ARQT.
Arcutis Biotherapeutics (ARQT) drew investor attention after reporting third quarter 2026 earnings, with net product revenue for ZORYVE up 45% year over year and full year sales guidance nudged higher. The reaction in Arcutis Biotherapeutics’ share price has been sharp, with the stock falling about 20.7% on the day and 15.8% over the past week. This comes even though the 30 day share price return is up 11.7% and the 1 year total shareholder return sits at 11.4%. The very large 3 year total...
Summary of Oct 20's posts. Generated by AI.
Summary of Oct 19's posts. Generated by AI.
Arcutis Biotherapeutics (ARQT) stock plunges as the company's Q3 2026 earnings falls short of forecasts amid higher costs. Read more here.
Summary of Dec 18's posts. Generated by AI.
Summary of Oct 19's posts. Generated by AI.
Investors talking about ARQT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.